# US 10,307,593 B2 · Automatic initiation of priming at startup of neuromodulation device > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,307,593 B2 - Document ID: US10307593B2 - Status: Granted - Kind: B2 - Application number: 15/610,839 - Filed: 2017-06-01 - Published: 2017-12-07 - Granted: 2019-06-04 - Earliest claimed: 2016-06-02 - Assignees: Boston Scientific Neuromodulation Corporation - Applicants: Boston Scientific Neuromodulation Corporation - Inventors: Que T. Doan; Bradley Lawrence Hershey; Changfang Zhu - Web page: https://patentgrep.com/patent/US10307593B2 ## CPC - A61N 1/36071: {Pain} - A61N 1/36021: {for treatment of pain} - A61N 1/36062: {Spinal stimulation} - A61N 1/36125: {Details of circuitry or electric components} - A61N 1/36164: {Sub-threshold or non-excitatory signals (non-excitatory signals to the heart A61N1/3628)} - A61N 1/36178: {Burst or pulse train parameters} - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) ## Abstract A neuromodulation system executes a set of startup operations. In response to completion of the startup operations, a priming field is automatically initiated. The priming field is to produce a priming effect in priming-targeted neural tissue, with the priming effect causing a change in sensitization to a therapeutic neuromodulation field of the priming-targeted neural tissue. The system also generates the therapeutic neuromodulation field to produce a therapeutic effect in therapy-targeted neural tissue. ## Claims ### Claim 1 Apparatus for a neuromodulation system, comprising: neuromodulation generator circuitry configured to use electrodes of an electrode arrangement to generate neuromodulation fields including: a therapeutic neuromodulation field to produce a perceptible therapeutic effect in therapy-targeted neural tissue; and a priming field to produce a sub-perception priming effect in priming-targeted neural tissue, wherein the sub-perception priming effect causes a change in sensitization of the priming-targeted neural tissue to the therapeutic neuromodulation field to be generated; and a controller configured to execute a set of startup operations of the neuromodulation system, the set of startup operations including determination of a type of the electrode arrangement, and to respond to completion of the execution of the set of startup operations by, independently of any user-originated instructions, determining the priming field based on the determined type of the electrode arrangement and causing the neuromodulation generator circuitry to initiate the determined priming field. ### Claim 2 (depends on 1) The apparatus of claim 1, further comprising the electrode arrangement. ### Claim 3 (depends on 1) The apparatus of claim 1, wherein the set of startup operations include in-situ electrical measurements adapted to assess placement of the electrode arrangement with respect to a patient. ### Claim 4 (depends on 1) The apparatus of claim 1, wherein the priming field is to be initiated in response to a default priming program, wherein the default priming program is initiated independently of any user-originated instructions. ### Claim 5 (depends on 4) The apparatus of claim 4, wherein the default priming program is based on an adjustable set of parameters that are adjusted based on a result of the set of startup operations. ### Claim 6 (depends on 1) The apparatus of claim 1, wherein the therapeutic neuromodulation field is focused onto the therapy-targeted neural tissue, and wherein the priming field is broadly distributed among the priming-targeted tissue, wherein a portion of the priming-targeted tissue includes the therapy-targeted tissue. ### Claim 7 (depends on 1) The apparatus of claim 1, wherein the change in sensitization of the priming-targeted neural tissue includes an increase in sensitivity of the priming-targeted neural tissue to the therapeutic neuromodulation field. ### Claim 8 (depends on 1) The apparatus of claim 1, wherein the priming field applies less energy than the therapeutic neuromodulation field. ### Claim 9 (depends on 1) The apparatus of claim 1, wherein the perceptible therapeutic effect includes pain relief. ### Claim 10 (depends on 1) The apparatus of claim 1, wherein the controller is operatively coupled to program instructions that, when executed, configure the controller to control the neuromodulation generator circuitry to generate the therapeutic neuromodulation field and the priming field. ### Claim 11 A method for operating a neuromodulation system to generate neuromodulation fields, the method comprising: executing a set of startup operations of the neuromodulation system, including determining a type of an electrode arrangement of the neuromodulation system, the electrode arrangement used for generating the neuromodulation fields; responding to completion of the set of startup operations by determining a priming field based on the determined type of the electrode arrangement and initiating generation of the determined priming field automatically and independently of any user-originated instructions, the priming field to produce a sub-perception priming effect in priming-targeted neural tissue, wherein the sub-perception priming effect causes a change in sensitization of the priming-targeted neural tissue to a therapeutic neuromodulation field to be generated; and generating the therapeutic neuromodulation field to produce a perceptible therapeutic effect in therapy-targeted neural tissue. ### Claim 12 (depends on 11) The method of claim 11, further comprising: providing an electrode arrangement that emits the priming field and the therapeutic neuromodulation field. ### Claim 13 (depends on 12) The method of claim 12, wherein executing the set of startup operations includes performing in-situ electrical measurements to assess placement of the electrode arrangement with respect to a patient. ### Claim 14 (depends on 11) The method of claim 11, wherein the priming field is initiated in response to execution of a default priming program, wherein the default priming program is initiated independently of any user-originated instructions. ### Claim 15 (depends on 14) The method of claim 14, wherein the default priming program is based on an adjustable set of parameters that are adjusted based on a result of the set of startup operations. ### Claim 16 (depends on 11) The method of claim 11, wherein the therapeutic neuromodulation field is focused onto the therapy-targeted neural tissue, and wherein the priming field is broadly distributed among the priming-targeted tissue, wherein a portion of the priming-targeted tissue includes the therapy-targeted tissue. ### Claim 17 (depends on 11) The method of claim 11, wherein the change in sensitization of the priming-targeted neural tissue includes an increase in sensitivity of the priming-targeted neural tissue to the therapeutic neuromodulation field. ### Claim 18 (depends on 11) The method of claim 11, wherein the priming field applies less energy than the therapeutic neuromodulation field.